● Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Condition: HER2-positive Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Sponsor: AstraZeneca

PhasePhase 3

Planned participants840

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (293)

Research Site	Anchorage, Alaska, United States	Recruiting
Research Site	Phoenix, Arizona, United States	Recruiting
Research Site	Duarte, California, United States	Recruiting
Research Site	Glendale, California, United States	Not Yet Recruiting
Research Site	La Jolla, California, United States	Recruiting
Research Site	Los Alamitos, California, United States	Not Yet Recruiting
Research Site	Los Angeles, California, United States	Recruiting
Research Site	Santa Monica, California, United States	Recruiting
Research Site	Solvang, California, United States	Recruiting
Research Site	Upland, California, United States	Recruiting
Research Site	Walnut Creek, California, United States	Recruiting
Research Site	Aurora, Colorado, United States	Recruiting

+ 281 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06764875